Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | hypothetical protein | 0.002 | 0 | 0.5 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.0276 | 0.3644 | 0.5 |
Entamoeba histolytica | leucine-rich repeat domain-containing protein | 0.002 | 0 | 0.5 |
Brugia malayi | Dihydrofolate reductase | 0.0723 | 1 | 0.5 |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0276 | 0.3644 | 0.5 |
Loa Loa (eye worm) | dihydrofolate reductase | 0.0723 | 1 | 0.5 |
Echinococcus multilocularis | dihydrofolate reductase | 0.0723 | 1 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.002 | 0 | 0.5 |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.0276 | 0.3644 | 0.5 |
Schistosoma mansoni | dihydrofolate reductase | 0.0723 | 1 | 0.5 |
Leishmania major | dihydrofolate reductase-thymidylate synthase | 0.0276 | 0.3644 | 0.5 |
Mycobacterium ulcerans | dihydrofolate reductase DfrA | 0.0723 | 1 | 0.5 |
Echinococcus granulosus | dihydrofolate reductase | 0.0723 | 1 | 0.5 |
Mycobacterium tuberculosis | Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) | 0.0723 | 1 | 0.5 |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.0276 | 0.3644 | 0.5 |
Chlamydia trachomatis | dihydrofolate reductase | 0.0723 | 1 | 0.5 |
Entamoeba histolytica | protein kinase, putative | 0.002 | 0 | 0.5 |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0276 | 0.3644 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.002 | 0 | 0.5 |
Mycobacterium leprae | DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) | 0.0723 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 83.06 uM | Cytotoxicity against Homo sapiens (human) HepG2 cells after 72 hr by MTT assay | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.